Feed/Companies/Vinci Pharmaceuticals Inc.

Vinci Pharmaceuticals Inc.

Every round on record, with the sources behind each and the investors on them.

Vinci Pharmaceuticals is disrupting retinal disease treatment with EPIPLANT™, a proprietary needle free drug delivery platform.

LATEST ROUND

Series A

$8M · 2026-10-01

RAISED ON RECORD · USD

$8M

1 round · $16.5M to date, as reported

INVESTORS

1 lead

SOURCES

from 6 publishers

Company

Every round on record, with the sources behind each and the investors on them.

Round	Amount	Announced	Lead	Buzz
Series A	$8M $16.5M to date	2026-10-01	Dynagrow Capital, LLLP	6 outlets. #15 in Trending
7 sources [ VERIFIED · CORRECTED ] read against 4 of 7 sources Date 2026-10-01 → 2026-10-08 · prnewswire.com The company release’s “$8+ million” amount is used over FinSMEs’ “over $8M”; the release also states the cumulative total of more than $16.5M.